AR105822A1 - Análogos de insulina - Google Patents

Análogos de insulina

Info

Publication number
AR105822A1
AR105822A1 ARP160102602A ARP160102602A AR105822A1 AR 105822 A1 AR105822 A1 AR 105822A1 AR P160102602 A ARP160102602 A AR P160102602A AR P160102602 A ARP160102602 A AR P160102602A AR 105822 A1 AR105822 A1 AR 105822A1
Authority
AR
Argentina
Prior art keywords
insulin analog
cys
leu
analog peptide
xaa
Prior art date
Application number
ARP160102602A
Other languages
English (en)
Inventor
Chang Kwon Se
Young Choi In
Kyu Lim Hyung
Soo Lee Jong
Lim Oh Euh
Young Kim Jin
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR105822A1 publication Critical patent/AR105822A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicación 1: Un péptido análogo de insulina que comprende una cadena A de SEQ ID Nº 3 indicada en la fórmula general (1) y una cadena B de SEQ ID Nº 4 indicada en la fórmula general (2), (fórmula general 1): Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Xaa-G1n-Leu-Glu-Asn-Tyr-Cys-Asn (SEQ ID Nº 3) en donde Xaa es ácido glutámico o asparragina; y (fórmula general 2): Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Xaa-Tyr-Thr-Pro-Lys-Thr (SEQ ID Nº 4) en donde Xaa es fenilalanina o está suprimido. Reivindicación 8: Un ácido nucleico que codifica el péptido análogo de insulina de acuerdo con una cualquiera de las reivindicaciones 1 a 7. Reivindicación 11: Un transformante que está transformado con el vector de expresión recombinante de acuerdo con la reivindicación 10. Reivindicación 13: Un método para preparar el péptido análogo de insulina de acuerdo con la reivindicación 1, que comprende: a) la preparación de un vector de expresión recombinante que comprende un ácido nucleico que codifica el péptido análogo de insulina de acuerdo con la reivindicación 1; b) la transformación del vector de expresión recombinante en una célula anfitriona y la obtención de un transformante de la misma; c) el cultivo del transformante y la expresión del péptido análogo de insulina; y d) el aislamiento y la purificación del péptido análogo de insulina expresado. Reivindicación 17: Una composición farmacéutica para el tratamiento de la diabetes que comprende el péptido análogo de insulina de acuerdo con una cualquiera de las reivindicaciones 1 a 7 y un portador farmacéuticamente aceptable.
ARP160102602A 2015-08-28 2016-08-25 Análogos de insulina AR105822A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20150121819 2015-08-28

Publications (1)

Publication Number Publication Date
AR105822A1 true AR105822A1 (es) 2017-11-15

Family

ID=58189026

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102602A AR105822A1 (es) 2015-08-28 2016-08-25 Análogos de insulina

Country Status (15)

Country Link
US (2) US10017557B2 (es)
EP (1) EP3341404B1 (es)
JP (2) JP6976930B2 (es)
KR (1) KR20170026284A (es)
CN (2) CN108350056B (es)
AR (1) AR105822A1 (es)
AU (1) AU2016317449B2 (es)
CA (1) CA2999823A1 (es)
EA (1) EA201890584A1 (es)
PH (1) PH12018500690A1 (es)
TW (1) TWI781083B (es)
UA (1) UA125928C2 (es)
UY (1) UY36870A (es)
WO (1) WO2017039267A1 (es)
ZA (1) ZA201802017B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36870A (es) * 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
WO2018056764A1 (ko) 2016-09-23 2018-03-29 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도
WO2018105988A1 (ko) 2016-12-05 2018-06-14 한미약품 주식회사 면역반응이 약화된 결합체
JP2020506932A (ja) 2017-02-03 2020-03-05 ハンミ ファーマシューティカル カンパニー リミテッド 持続性が増加した生理活性物質の結合体及びその用途
TWI798209B (zh) 2017-03-23 2023-04-11 南韓商韓美藥品股份有限公司 對胰島素受體有降低親和性之胰島素類似物之接合物及其用途
EP3900734A4 (en) 2018-12-21 2022-10-12 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION WITH INSULIN AND GLUCAGON
US20220088148A1 (en) 2018-12-21 2022-03-24 Hanmi Pharm, Co., Ltd. A pharmaceutical composition comprising insulin and trigonal glucagon/glp-1/gip receptor agonist
CN111220604B (zh) * 2019-12-06 2022-03-15 东北农业大学 一种肉制品中总淀粉含量的测定方法
KR102663243B1 (ko) 2021-08-30 2024-05-03 국립순천대학교산학협력단 트립신 특이적 형광 프로브 및 이의 용도
KR102574341B1 (ko) 2021-08-30 2023-09-04 순천대학교 산학협력단 아미노산 특이적 차단제 및 이의 용도
CN114805544B (zh) * 2022-06-23 2022-09-09 北京惠之衡生物科技有限公司 一种赖脯胰岛素前体、其重组基因工程菌及其构建方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2536040A1 (de) 1975-08-13 1977-02-24 Hoechst Ag Insulin-analoga mit biologischer wirkung
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5716927A (en) * 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
JPH04502465A (ja) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
US5422339A (en) 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
ATE284415T1 (de) * 1999-01-06 2004-12-15 Genentech Inc Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
CN1635900A (zh) 2001-08-28 2005-07-06 伊莱利利公司 Glp－1和基础胰岛素的预混合物
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
EP1448222A4 (en) 2001-10-19 2006-05-17 Lilly Co Eli BIPHASIC MIXTURES OF GLP-1 AND INSULIN
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
AU2004234345A1 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
SI1648933T1 (sl) 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Dolgo delujoäś inzulinski derivat in metoda zanj
ES2372495T3 (es) 2003-11-13 2012-01-20 Hanmi Holdings Co., Ltd Método para la producción en masa de la región constante de inmunoglobulina.
JP5366546B2 (ja) 2005-08-16 2013-12-11 ノボ・ノルデイスク・エー／エス 成熟インスリンポリペプチドの作製方法
PL2074141T3 (pl) * 2006-09-22 2017-02-28 Novo Nordisk A/S Analogi insuliny oporne na proteazę
US7790677B2 (en) 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP2170945A1 (en) 2007-07-16 2010-04-07 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
EP2017288A1 (en) 2007-07-16 2009-01-21 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
US8575096B2 (en) * 2007-08-13 2013-11-05 Novo Nordisk A/S Rapid acting insulin analogues
EP2708554A1 (en) 2007-08-15 2014-03-19 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
CN101157725B (zh) * 2007-10-24 2012-07-25 中国药科大学 人胰岛素类似物的制备方法及用途
CN107115523A (zh) 2007-11-16 2017-09-01 诺沃—诺迪斯克有限公司 包含glp‑1肽或毒蜥外泌肽‑4和基础胰岛素肽的药物组合物
BRPI0907371A2 (pt) 2008-01-09 2015-11-24 Sanofi Aventis Deutschland derivados de insulina com um perfil de tempo-ação muito retardado
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
JP5695909B2 (ja) 2008-01-09 2015-04-08 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
EP2254905B1 (en) * 2008-03-14 2016-12-14 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910570B1 (en) 2008-03-18 2016-10-12 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
WO2009129250A2 (en) 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
MX2010011329A (es) * 2008-04-22 2011-03-15 Univ Case Western Reserve Analogos de insulina especificos de isoforma.
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
CN102256992B (zh) 2008-12-19 2015-04-22 印第安纳大学研究及科技有限公司 胰岛素类似物
JP5755566B2 (ja) 2008-12-19 2015-07-29 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ アミド系インスリンプロドラッグ
MA33221B1 (fr) 2009-03-27 2012-04-02 Glaxo Group Ltd Fusions de médicament et conjugués afférents
WO2011028813A2 (en) 2009-09-01 2011-03-10 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
RU2537239C2 (ru) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
KR101058209B1 (ko) 2009-12-30 2011-08-22 전자부품연구원 Ｏｆｄｍ 방식의 디지털 방송 시스템의 빠른 동기 방법
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) * 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
KR101330868B1 (ko) 2010-06-08 2013-11-18 한미사이언스 주식회사 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체
EP2582719B1 (en) * 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
WO2012015692A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
KR20120013727A (ko) 2010-08-06 2012-02-15 삼성전자주식회사 디스플레이장치 및 그 제어방법
EA201390796A1 (ru) 2011-01-20 2014-07-30 Зилэнд Фарма А/С Применение ацилированного аналога глюкагона
WO2012116818A1 (en) 2011-03-02 2012-09-07 Oerlikon Trading Ag, Trübbach Sliding component coated with metal-comprising carbon layer for improving wear and friction behavior by tribological applications under lubricated conditions
CN102675452B (zh) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
US9341445B2 (en) 2011-05-03 2016-05-17 Teijin Aramid Bv Antiballistic panel with first and second laminates having fibers of different tensile modulus
WO2012167251A1 (en) 2011-06-02 2012-12-06 Prolor Biotech Inc. Long-acting glp-1/glucagon receptor agonists
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
DK2718318T3 (en) 2011-06-10 2018-11-05 Hanmi Science Co Ltd New oxyntomodulin derivatives and pharmaceutical compositions for the treatment of obesity comprising these
WO2012173422A1 (en) 2011-06-17 2012-12-20 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
US9165768B2 (en) 2011-12-16 2015-10-20 Lg Innotek Co., Ltd. Method for deposition of silicon carbide and silicon carbide epitaxial wafer
EP2804621A4 (en) 2012-01-20 2015-11-18 Univ Case Western Reserve GLUTAMINE-SAFE STABILIZED INSULIN ANALOG
CN104136626B (zh) * 2012-03-01 2017-05-03 诺沃—诺迪斯克有限公司 N‑末端修饰的寡肽及其用途
KR101665009B1 (ko) 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
EA034499B1 (ru) 2012-11-06 2020-02-13 Ханми Фарм. Ко., Лтд. Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
TWI755579B (zh) * 2013-02-26 2022-02-21 南韓商韓美藥品股份有限公司 新穎胰島素類似物及其用途
MX361083B (es) * 2013-02-26 2018-11-27 Hanmi Pharma Co Ltd Conjugado de insulina específico de sitio.
MA43289B1 (fr) * 2014-01-20 2019-12-31 Hanmi Pharm Ind Co Ltd Insuline à action prolongée et utilisation associée
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
KR101676542B1 (ko) * 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos

Also Published As

Publication number Publication date
US10017557B2 (en) 2018-07-10
JP6976930B2 (ja) 2021-12-08
EP3341404C0 (en) 2024-04-03
JP2018526001A (ja) 2018-09-13
AU2016317449A1 (en) 2018-04-19
KR20170026284A (ko) 2017-03-08
UY36870A (es) 2017-03-31
UA125928C2 (uk) 2022-07-13
EP3341404B1 (en) 2024-04-03
AU2016317449B2 (en) 2021-01-07
CN108350056A (zh) 2018-07-31
EP3341404A1 (en) 2018-07-04
TW201710288A (zh) 2017-03-16
TWI781083B (zh) 2022-10-21
ZA201802017B (en) 2019-01-30
JP2021168687A (ja) 2021-10-28
US20170066811A1 (en) 2017-03-09
CN108350056B (zh) 2021-09-21
JP7252280B2 (ja) 2023-04-04
PH12018500690A1 (en) 2018-10-15
WO2017039267A1 (en) 2017-03-09
EA201890584A1 (ru) 2018-08-31
US10647753B2 (en) 2020-05-12
EP3341404A4 (en) 2019-08-21
CA2999823A1 (en) 2017-03-09
US20180282388A1 (en) 2018-10-04
CN113637065A (zh) 2021-11-12

Similar Documents

Publication Publication Date Title
AR105822A1 (es) Análogos de insulina
PE20170950A1 (es) Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos
MY176332A (en) Multispecific antibody constructs
MX2022003908A (es) Enzimas y aplicaciones de las mismas.
ES2693321T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
AR093903A1 (es) Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad
AR090469A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
BR112016015187A2 (pt) proteína de fusão para inibição da angiogênese ou do crescimento e uso da mesma
PE20181176A1 (es) Composiciones biofarmaceuticas
CL2018000164A1 (es) Vector recombinante del virus orf.
AR110093A1 (es) D-psicosa 3-epimerasa y método para preparar d-psicosa utilizando la misma
MX2019003360A (es) Vectores de expresion para una secrecion de proteina mejorada.
AR100310A1 (es) Moléculas para transporte de antígeno modular mejoradas y sus usos
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
AR101597A1 (es) Proteínas de fusión uti (inhibidor de tripsina urinaria)
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
AR083533A1 (es) Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
MY187334A (en) Xylanase
NZ603442A (en) Treatment of proliferative diseases
NZ709120A (en) Beta-hexosyl-transferases and uses thereof
AR083766A1 (es) Peptido inmunogenico
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
AR102803A1 (es) Vacunas de reovirus aviar
GB201018125D0 (en) Peptide